Effectiveness and safety of vedolizumab in a matched cohort of elderly and young Inflammatory Bowel Disease patients - LIVE Study-Group

被引：0
|
作者：
Pugliese, D. [1 ]
Privitera, G. [2 ]
Armuzzi, A. [3 ]
机构：
[1] Fdn Policlin Univ Agostino Gemelli IRCCS, CEMAD IBD UNIT, Unita Operat Complessa Med Interna & Gastroentero, Rome, Italy
[2] Univ Cattolica Sacro Cuore, Dipartimento Univ Med & Chirurg Traslaz, Rome, Italy
[3] Univ Cattolica, Fdn Policlin Univ Agostino Gemelli IRCCS, CEMAD IBD Unit, Unita Operat Complessa Med Interna & Gastroentero, Rome, Italy
来源：
JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷
关键词：
D O I：
10.1093/ecco-jcc/jjab073.088
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP49
引用
收藏
页码：S085 / S085
页数：1
相关论文
共 50 条
  • [41] Comparative Effectiveness and Safety of Denosumab Versus Bisphosphonates in Osteoporosis Management Among Patients with Inflammatory Bowel Disease: A US Propensity Matched Cohort Study
    Khataniar, H.
    Desai, A.
    Kochhar, G.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1366 - i1367
  • [42] Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
    Poylin, Vitaliy Y.
    Serrato, Jose Cataneo
    Del Valle, Jonathan Pastrana
    Feuerstein, Joseph D.
    INTESTINAL RESEARCH, 2022, 20 (01) : 72 - 77
  • [43] Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety
    Christensen, Britt
    Colman, Ruben J.
    Micic, Dejan
    Gibson, Peter R.
    Goeppinger, Sarah R.
    Yarur, Andres
    Weber, Christopher R.
    Cohen, Russell D.
    Rubin, David T.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (04) : 849 - 860
  • [44] Effectiveness and Safety of Vedolizumab in Anti-TNF-Naive Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study
    Kopylov, Uri
    Verstockt, Bram
    Biedermann, Luc
    Sebastian, Shaji
    Pugliese, Daniela
    Sonnenberg, Elena
    Steinhagen, Peter
    Arebi, Naila
    Ron, Yulia
    Kucharzik, Torsten
    Roblin, Xavier
    Ungar, Bella
    Shitrit, Ariella Bar-Gil
    Ardizzone, Sandro
    Molander, Pauliina
    Coletta, Marina
    Peyrin-Biroulet, Laurent
    Bossuyt, Peter
    Avni-Biron, Irit
    Tsoukali, Emmanouela
    Allocca, Mariangela
    Katsanos, Konstantinos
    Raine, Tim
    Sipponen, Taina
    Fiorino, Gionata
    Ben-Horin, Shomron
    Eliakim, Rami
    Armuzzi, Alessandro
    Siegmund, Britta
    Baumgart, Daniel C.
    Kamperidis, Nikolaos
    Maharshak, Nitsan
    Maaser, Christian
    Mantzaris, Gerassimos
    Yanai, Henit
    Christodoulou, Dimitrious K.
    Dotan, Iris
    Ferrante, Marc
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (11) : 2442 - 2451
  • [45] Effectiveness of Vedolizumab in Patients With Inflammatory Bowel Disease and Concomitant Primary Sclerosing Cholangitis
    Santiago, Priscila
    Robateau, Anthony
    Lopdrup, Rachel G.
    Neto, Manuel B. Braga
    Raffals, Laura
    Eaton, John
    Ramos, Guilherme
    Loftus, Edward V.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S688 - S689
  • [46] Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience
    Ibraheim, Hajir
    Samaan, Mark A.
    Srinivasan, Ashish
    Brain, Oliver
    Digby-Bell, Jonathan
    Irving, Peter M.
    Norman, Irena
    Jawad, Issrah
    Biedermann, Julia
    Ibarra, Ana
    Kok, Klaartje Bel
    Parkes, Gareth
    Rimmer, Joanna
    Compot, Elisabeta
    Parkes, Miles
    Segal, Jonathan
    Oppong, Philip
    Hart, Ailsa
    Hayee, Bu'Hussain
    Powell, Nick
    ANNALS OF GASTROENTEROLOGY, 2020, 33 (02): : 170 - +
  • [47] Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission
    Parisio, Laura
    Settanni, Carlo Romano
    Varca, Simone
    Laterza, Lucrezia
    Lopetuso, Loris Riccardo
    Napolitano, Daniele
    Schiavoni, Elisa
    Turchini, Laura
    Fanali, Caterina
    Alfieri, Norma
    Pizzoferrato, Marco
    Papa, Alfredo
    Pafundi, Pia Clara
    Armuzzi, Alessandro
    Gasbarrini, Antonio
    Pugliese, Daniela
    Scaldaferri, Franco
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2023, 32 (04) : 452 - 459
  • [48] Comparing Ustekinumab and Vedolizumab in Inflammatory Bowel Disease Patients Exposed to Anti-TNF Agents: A Propensity-Matched, Retrospective Cohort Study
    Aksan, Feyzullah
    Barrera, Layla
    Ullman, Thomas
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S772 - S772
  • [49] Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
    Alshahrani, Abdulaziz Saad
    Mohammad, Danah
    Alzahrani, Mohammad Attieh
    Narula, Neeraj
    SAUDI PHARMACEUTICAL JOURNAL, 2023, 31 (09)
  • [50] vedolizumab Does Not Increase Risk of Clostridium Difficile Infection in Patients with Inflammatory Bowel Disease Using vedolizumab: a Retrospective Cohort Study
    Alshahrani, A.
    Alzahrani, Danah Mohammad Attieh
    Narula, Neeraj
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I326 - I326
12345